-
Medicina Oral, Patologia Oral Y Cirugia... May 2019The objective of this study was to evaluate the quality of life and the presence of anxiety and depression in patients with dysgeusia post halitosis treatment.
BACKGROUND
The objective of this study was to evaluate the quality of life and the presence of anxiety and depression in patients with dysgeusia post halitosis treatment.
MATERIAL AND METHODS
Sixty patients were divided into three groups: Dysgeusia group (DG); Halitosis group (HG) and Control group (CG). The following instruments were used: Medical results study Short form health research of 36 items (SF-36), State-state anxiety inventory (STAI) and Self-report questionnaire-20 (SRQ-20).
RESULTS
Of the 60 subjects studied, 85% were female and 15% were male. The evaluation of SF-36 indicated a statistically significant correlation between some domains for DG and showed low scores for Mental Health. In relation to HG, low scores were obtained for Bodily Pain, Vitality and Emotional Role. The CG showed low scores for Bodily Pain, General Health and Vitality. STAI was significant when DG was compared to HG and CG. The mean SRQ-20 score was higher in DG compared with the other groups.
CONCLUSIONS
Persistent dysgeusia post-halitosis treatment impacts on QoL generically in the Mental health domain, and specifically in trait and state anxiety. Symptoms of depression were also seen in this group of patients.
Topics: Anxiety; Depression; Dysgeusia; Female; Halitosis; Humans; Male; Quality of Life; Surveys and Questionnaires
PubMed: 31041914
DOI: 10.4317/medoral.22370 -
International Journal of Radiation... Oct 2016Dysgeusia is a significant factor reducing quality of life and worsening dysphagia in patients receiving chemoradiation therapy for head and neck cancer. The factors... (Clinical Trial)
Clinical Trial
OBJECTIVE(S)
Dysgeusia is a significant factor reducing quality of life and worsening dysphagia in patients receiving chemoradiation therapy for head and neck cancer. The factors affecting dysgeusia severity are uncertain. We investigated the effects on patient-reported dysgeusia of doses to the oral cavity, salivary output (required to dissolve food particles), and patient-reported xerostomia.
METHODS AND MATERIALS
Seventy-three patients with stage III to IV oropharyngeal cancer (OPC) (N=73) receiving definitive intensity modulated radiation therapy concurrently with chemotherapy participated in a prospective, longitudinal study of quality of life (QOL), including assessment of patient-reported gustatory function by taste-related questions from the Head and Neck QOL instrument (HNQOL) and the University of Washington Head and Neck-related QOL instrument (UWQOL), before therapy and periodically after treatment. At these intervals, patients also completed a validated xerostomia-specific questionnaire (XQ) and underwent unstimulated and stimulated major salivary gland flow rate measurements.
RESULTS
At 1, 3, 6, and 12 months after treatment, dysgeusia improved over time: severe dysgeusia was reported by 50%, 40%, 22%, and 23% of patients, respectively. Significant associations were found between patient-reported severe dysgeusia and radiation dose to the oral cavity (P=.005) and tongue (P=.019); normal tissue complication probability for severe dysgeusia at 3 months showed mean oral cavity D50 doses 53 Gy and 57 Gy in the HNQOL and WUQOL questionnaires, respectively, with curve slope (m) of 0.41. Measured salivary output was not statistically significantly correlated with severe taste dysfunction, whereas patient-reported XQ summary scores and xerostomia while eating scores were correlated with severe dysgeusia in the UWQOL tool (P=.04).
CONCLUSIONS
Taste impairment is significantly correlated with mean radiation dose to the oral cavity. Patient-reported xerostomia, but not salivary output, was correlated with severe dysgeusia in 1 of the 2 QOL questionnaires. Reduction in oral cavity doses is likely to improve dysgeusia.
Topics: Adult; Aged; Causality; Chemoradiotherapy; Comorbidity; Dysgeusia; Female; Humans; Incidence; Longitudinal Studies; Male; Michigan; Middle Aged; Organ Sparing Treatments; Oropharyngeal Neoplasms; Quality of Life; Radiotherapy Dosage; Radiotherapy, Conformal; Risk Factors; Treatment Outcome; Xerostomia
PubMed: 27473816
DOI: 10.1016/j.ijrobp.2016.05.011 -
Supportive Care in Cancer : Official... Dec 2019Taste disorders are one of the most common side effects of treatment in oncology patients and often occur after allogeneic haematopoietic cell transplantation...
BACKGROUND
Taste disorders are one of the most common side effects of treatment in oncology patients and often occur after allogeneic haematopoietic cell transplantation (allo-HCT). Dysgeusia does not receive close medical attention, and information about this disorder is largely based on the clinician's own experience. However, taste disorders can have an impact on the quality of life and nutritional status of survivors of allo-HCT. The number of performed annual transplantations is growing, as the number of older long-term survivors increases, but only few research studies examine survivors of allo-HCT with taste disorders. We conducted a qualitative descriptive study to explore experiences of dysgeusia in patients undergoing allo-HCT and to examine what strategies they used to mitigate it.
METHODS
Using purposeful sampling, survivors of allo-HCT were recruited. Audiotape interviews were conducted until data saturation was achieved. Each interview was transcribed verbatim, and content analyses were performed to extract significant themes and subthemes.
RESULTS
Three major themes embracing various aspects of allo-HCT survivors' experiences were identified: (1) the shape of taste; (2) everything is irritating and it is arduous to eat; (3) finding new strategies to overcome the problems. Together, they highlight the experiences of survivors showing how the taste disorders can affect the physical, psychological and social dimensions of a person.
CONCLUSION
A cumulative burden is the result of dysgeusia and its clinical course reinforced also by related symptoms. Healthcare professionals must focus their attention on the management of these symptoms and offer interventions to safeguard the patient's social, physical and psychological well-being.
Topics: Dysgeusia; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nutritional Status; Qualitative Research; Quality of Life; Survivors; Taste
PubMed: 30937598
DOI: 10.1007/s00520-019-04769-2 -
Clinical Toxicology (Philadelphia, Pa.) Aug 2011In March 2008, French poison centres (PCs) recorded the first calls reporting persistent bitterness following the ingestion of pine nuts.
INTRODUCTION
In March 2008, French poison centres (PCs) recorded the first calls reporting persistent bitterness following the ingestion of pine nuts.
METHODS
The French toxic exposure surveillance system (French-Tess) was searched and a descriptive analysis of cases was performed on data recorded from 13 March 2008 to 31 January 2010.
RESULTS
Some 3111 cases of bitterness were reported to PCs. The number of cases rose sharply from May 2009 to reach a peak in August 2009 with 697 cases. The median time to onset of dysgeusia was 24 hours and it lasted less than 14 days in 95% of cases. Raw as well as cooked or processed pine nuts were implicated.
DISCUSSION
The delayed onset and persistence of dysgeusia suggest that the toxin may act via an unknown toxic mechanism on the receptor. The aetiological agent could be an unidentified toxin present in some varieties of non-edible pine nuts.
CONCLUSION
The high incidence of the event and the lack of understanding of the nature of the toxin and its pathophysiological mechanism require continued monitoring of poison cases, botanical and biochemical analysis, and experimental studies.
Topics: Adult; Dysgeusia; Female; France; Humans; Incidence; Male; Nuts; Pinus; Poison Control Centers; Receptors, G-Protein-Coupled; Retrospective Studies; Taste Buds; Time Factors
PubMed: 21819292
DOI: 10.3109/15563650.2011.595721 -
Gan To Kagaku Ryoho. Cancer &... Aug 2013Chemotherapy for cancer has been reported to have many side effects. Dysgeusia or taste disorder is a common complaint among cancer patients undergoing ambulatory...
Chemotherapy for cancer has been reported to have many side effects. Dysgeusia or taste disorder is a common complaint among cancer patients undergoing ambulatory chemotherapy. The present study was undertaken to establish the importance of dysgeusia as a side effect of chemotherapy in these patients. The study included 356 patients who visted Shikoku Cancer Center to undergo outpatient cancer chemotherapy. Of these patients, 156(43.8%)experienced dysgeusia. Of the 156 patients, 34 were male and 122 were female. The incidence of dysgeusia was higher in patients receiving FOLFOX6(oxaliplatin+ 5-FU), docetaxel(DTX), paclitaxel(PTX), docetaxel+cyclophosphamide(TC)or epirubicin+cyclophosphamide(EC) than in those receiving other regimens. When the occurrence of dysgeusia was difficult to define, the changes in taste sensations were subtle for salty and umami taste. This disorder affected appetite: 87.2%of patients experienced loss of appetite. In addition, 66.7% of patients were distressed by this disorder. Dysgeusia may significantly reduce the quality of life of patients undergoing chemotherapy for cancer. Therefore, patient support is important for patients who experience dysgeusia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appetite; Dysgeusia; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Surveys and Questionnaires
PubMed: 23986049
DOI: No ID Found -
Annals of Internal Medicine Jul 1998
Topics: Aged; Antihypertensive Agents; Dysgeusia; Female; Humans; Losartan; Middle Aged
PubMed: 9653007
DOI: 10.7326/0003-4819-129-1-199807010-00023 -
The American Journal of Gastroenterology Mar 2007
Topics: Aged; Azathioprine; Colitis, Ulcerative; Colonoscopy; Dysgeusia; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Severity of Illness Index; Taste
PubMed: 17335457
DOI: 10.1111/j.1572-0241.2007.01040_6.x -
Journal of Dental Research Oct 2023COVID-19, mainly manifested as acute respiratory distress syndrome, has afflicted millions of people worldwide since 2019. Taste dysfunction is a common early-stage... (Review)
Review
COVID-19, mainly manifested as acute respiratory distress syndrome, has afflicted millions of people worldwide since 2019. Taste dysfunction is a common early-stage symptom of COVID-19 infection that burdens patients for weeks or even permanently in some cases. Owing to its subjectivity and complexity, the mechanism of taste disorder is poorly studied. Previous studies have reported that the COVID-19 entry receptors are highly expressed in taste buds, thereby intensifying the cytocidal effect. Taste receptor cells are vulnerable to inflammation, and the COVID-19-induced cytokine storm causes secondary damage to taste function. Interferon and various proinflammatory cytokines can trigger cell apoptosis and disrupt the renewal of taste bud stem cells. This immune response can be further enhanced by the accumulation of Angiotensin II (Ang II) caused by an unbalanced local renin-angiotensin system (RAS) system. In addition, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is neurotropic and can invade the brain through the olfactory bulb, affecting the nervous system. Other factors, such as host zinc deficiency, genetic susceptibility, sialic acid, and some neurotransmitters, also contribute to the pathogenesis process. Although several medical interventions have displayed effectiveness, only a few strategies exist for the treatment of postinfectious dysgeusia. Stem cell-based taste regeneration offers promise for long-term taste disorders. Clinical studies have demonstrated that stem cells can treat long COVID-19 through immune regulation. In dysgeusia, the differentiation of taste bud stem cells can be stimulated through exogenous epithelial-derived and neural-derived factors to regenerate taste buds. Tongue organoids are also emerging as functional taste buds, offering new insights into the study of taste regeneration. This review presents the current evidence of the pathogenesis of COVID-19-related dysgeusia, summarizes currently available treatments, and suggests future directions of taste regeneration therapy.
Topics: Humans; COVID-19; SARS-CoV-2; Dysgeusia; Post-Acute COVID-19 Syndrome; Taste Disorders; Taste Buds; Taste
PubMed: 37729625
DOI: 10.1177/00220345231182926 -
Journal of the American Dietetic... Nov 1983The results of this study indicate that patients with dysgeusia can be classified into groups on the basis of the number and kinds of foods and beverages they perceive...
The results of this study indicate that patients with dysgeusia can be classified into groups on the basis of the number and kinds of foods and beverages they perceive as distorted. Furthermore, a relationship between this classification and weight loss has been demonstrated, suggesting that caloric intake is decreased, particularly in patients with Type III and IV. The symptoms of dysgeusia worsened in 41% of all patients. These patients had sought medical help more quickly than any other patients with dysgeusia. An elevation in dysgeusia type (increase in severity) occurred in only a small number of patients, and no patient exhibited any improvement in dysgeusia once it occurred. Specific types of foods and beverages were commonly distorted in these patients. To characterize these abnormalities, we used six common food groups. On occasion, patients would eliminate an entire food group from their diets; if the nutrients contained in these foods could not be obtained from other dietary sources or if the food aversion persisted long enough (16), these patients could develop nutritional deficiencies. A nutritional history, using a standard form, was selected as the method for collecting data. Classification might have been even more accurate if a standardized food array had been used as part of this study. Indeed, we have developed such an array consisting of 120 food items and have since used it in conjunction with a diet history to evaluate patients with dysgeusia. Preliminary results confirm its usefulness in the classification described in this article.(ABSTRACT TRUNCATED AT 250 WORDS)
Topics: Adult; Aged; Body Weight; Dysgeusia; Female; Humans; Male; Middle Aged; Taste Disorders; Time Factors
PubMed: 6630821
DOI: No ID Found -
Internal Medicine (Tokyo, Japan) 2008Total dysgeusia, an inability to interpret all of the basic tastes, often occurs with zinc deficiency. Partial dysgeusia (dissociation dysgeusia) is a rare inability to...
Total dysgeusia, an inability to interpret all of the basic tastes, often occurs with zinc deficiency. Partial dysgeusia (dissociation dysgeusia) is a rare inability to interpret a limited number of these basic tastes. We present the case of a patient with myasthenia gravis who became unable to discern sweet taste, but other basic tastes were unaffected. Such dysgeusia can be explained by obstruction of selective taste receptors in taste cells. We considered that this symptom was induced by an autoimmune mechanism related to myasthenia gravis.
Topics: Adult; Autoimmunity; Dysgeusia; Humans; Male; Myasthenia Gravis; Sweetening Agents; Thymoma; Thyroid Neoplasms
PubMed: 18451583
DOI: 10.2169/internalmedicine.47.0735